Article | Published:

Intestinal dysbiosis compromises alveolar macrophage immunity to Mycobacterium tuberculosis



Current treatments for tuberculosis (TB) are effective in controlling Mycobacterium tuberculosis (Mtb) growth, yet have significant side effects and do not prevent reinfection. Therefore, it is critical to understand why our host defense system is unable to generate permanent immunity to Mtb despite prolonged anti-tuberculosis therapy (ATT). Here, we demonstrate that treatment of mice with the most widely used anti-TB drugs, rifampicin (RIF) or isoniazid (INH) and pyrazinamide (PYZ), significantly altered the composition of the gut microbiota. Unexpectedly, treatment of mice with the pro-Mtb drugs INH and PYZ, but not RIF, prior to Mtb infection resulted in an increased bacterial burden, an effect that was reversible by fecal transplantation from untreated animals. Mechanistically, susceptibility of INH/PYZ-treated mice was associated with impaired metabolism of alveolar macrophages and defective bactericidal activity. Collectively, these data indicate that dysbiosis induced by ATT administered to millions of individuals worldwide may have adverse effects on the anti-Mtb response of alveolar macrophages.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.

Additional information

Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.


  1. 1.

    Cobat, A. et al. Two loci control tuberculin skin test reactivity in an area hyperendemic for tuberculosis. J. Exp. Med. 206, 2583–2591 (2009).

  2. 2.

    Morrison, J., Pai, M. & Hopewell, P. C. Tuberculosis and latent tuberculosis infection in close contacts of people with pulmonary tuberculosis in low-income and middle-income countries: a systematic review and meta-analysis. Lancet Infect. Dis. 8, 359–368 (2008).

  3. 3.

    Menzies, D. et al. Four months of rifampin or nine months of isoniazid for latent tuberculosis in adults. N. Eng. J. Med. 379, 440–453 (2018).

  4. 4.

    Yew, W. W. & Leung, C. C. Antituberculosis drugs and hepatotoxicity. Respirology 11, 699–707 (2006).

  5. 5.

    Pai, M. et al. Tuberculosis. Nat. Rev. Dis. Prim. 2, 16076 (2016).

  6. 6.

    Cox, H. et al. Tuberculosis recurrence and mortality after successful treatment: impact of drug resistance. PLoS. Med. 3, e384 (2006).

  7. 7.

    Verver, S. et al. Rate of reinfection tuberculosis after successful treatment is higher than rate of new tuberculosis. Am. J. Respir. Crit. Care. Med. 171, 1430–1435 (2005).

  8. 8.

    Becattini, S., Taur, Y. & Pamer, E. G. Antibiotic-induced changes in the intestinal microbiota and disease. Trends Mol. Med. 22, 458–478 (2016).

  9. 9.

    Becattini, S. et al. Commensal microbes provide first line defense against Listeria monocytogenes infection. J. Exp. Med. 214, 1973–1989 (2017).

  10. 10.

    Khosravi, A. et al. Gut microbiota promote hematopoiesis to control bacterial infection. Cell Host. Microbe 15, 374–381 (2014).

  11. 11.

    Sekirov, I. et al. Antibiotic-induced perturbations of the intestinal microbiota alter host susceptibility to enteric infection. Infect. Immun. 76, 4726–4736 (2008).

  12. 12.

    Abt, M. C. et al. Commensal bacteria calibrate the activation threshold of innate antiviral immunity. Immunity 37, 158–170 (2012).

  13. 13.

    Khan, N. et al. Alteration in the gut microbiota provokes susceptibility to tuberculosis. Front. Immunol. 7, 529 (2016).

  14. 14.

    Rastogi, N. & David, H. L. Mode of action of antituberculous drugs and mechanisms of drug resistance in Mycobacterium tuberculosis. Res. Microbiol. 144, 133–143 (1993).

  15. 15.

    Namasivayam, S. et al. Longitudinal profiling reveals a persistent intestinal dysbiosis triggered by conventional anti-tuberculosis therapy. Microbiome 5, 71 (2017).

  16. 16.

    Wipperman, M. F. et al. Antibiotic treatment for Tuberculosis induces a profound dysbiosis of the microbiome that persists long after therapy is completed. Sci. Rep. 7, 10767 (2017).

  17. 17.

    Huber, W. et al. Orchestrating high-throughput genomic analysis with bioconductor. Nat. Methods 12, 115–121 (2015).

  18. 18.

    Lyadova, I. V. & Panteleev, A. V. Th1 and Th17 cells in tuberculosis: protection, pathology, and biomarkers. Mediat. Inflamm. 2015, 854507 (2015).

  19. 19.

    Shafiani, S., Tucker-Heard, G., Kariyone, A., Takatsu, K. & Urdahl, K. B. Pathogen-specific regulatory T cells delay the arrival of effector T cells in the lung during early tuberculosis. J. Exp. Med. 207, 1409–1420 (2010).

  20. 20.

    Hrncir, T., Stepankova, R., Kozakova, H., Hudcovic, T. & Tlaskalova-Hogenova, H. Gut microbiota and lipopolysaccharide content of the diet influence development of regulatory T cells: studies in germ-free mice. BMC Immunol. 9, 65 (2008).

  21. 21.

    Zhou, R., Yazdi, A. S., Menu, P. & Tschopp, J. A role for mitochondria in NLRP3 inflammasome activation. Nature 469, 221–225 (2011).

  22. 22.

    Kalghatgi, S. et al. Bactericidal antibiotics induce mitochondrial dysfunction and oxidative damage in Mammalian cells. Sci. Transl. Med 5, 192ra185 (2013).

  23. 23.

    Shi, C. & Pamer, E. G. Monocyte recruitment during infection and inflammation. Nat. Rev. Immunol. 11, 762–774 (2011).

  24. 24.

    Skold, M. & Behar, S. M. Tuberculosis triggers a tissue-dependent program of differentiation and acquisition of effector functions by circulating monocytes. J. Immunol. 181, 6349–6360 (2008).

  25. 25.

    Cohen, S. B. et al. Alveolar macrophages provide an early mycobacterium tuberculosis niche and initiate dissemination. Cell Host. Microbe 24, 439–446 e434 (2018).

  26. 26.

    Atarashi, K. et al. Treg induction by a rationally selected mixture of Clostridia strains from the human microbiota. Nature 500, 232–236 (2013).

  27. 27.

    Human Microbiome Project, C. Structure, function and diversity of the healthy human microbiome. Nature 486, 207–214 (2012).

  28. 28.

    Clarke, T. B. Early innate immunity to bacterial infection in the lung is regulated systemically by the commensal microbiota via nod-like receptor ligands. Infect. Immun. 82, 4596–4606 (2014).

  29. 29.

    Kim, Y. G. et al. Gut dysbiosis promotes M2 macrophage polarization and allergic airway inflammation via fungi-induced PGE(2). Cell Host. Microbe 15, 95–102 (2014).

  30. 30.

    Thaiss, C. A., Zmora, N., Levy, M. & Elinav, E. The microbiome and innate immunity. Nature 535, 65–74 (2016).

  31. 31.

    Hall, C. J. et al. Immunoresponsive gene 1 augments bactericidal activity of macrophage-lineage cells by regulating beta-oxidation-dependent mitochondrial ROS production. Cell Metab. 18, 265–278 (2013).

  32. 32.

    Gleeson, L. E. et al. Cutting edge: mycobacterium tuberculosis induces aerobic glycolysis in human alveolar macrophages that is required for control of intracellular bacillary replication. J. Immunol. 196, 2444–2449 (2016).

  33. 33.

    Huang, L., Nazarova, E. V., Tan, S., Liu, Y. & Russell, D. G. Growth of Mycobacterium tuberculosis in vivo segregates with host macrophage metabolism and ontogeny. J. Exp. Med. 215, 1135–1152 (2018).

  34. 34.

    Piccini, A. et al. ATP is released by monocytes stimulated with pathogen-sensing receptor ligands and induces IL-1beta and IL-18 secretion in an autocrine way. Proc. Natl. Acad. Sci. USA 105, 8067–8072 (2008).

  35. 35.

    Yao, Y. et al. Induction of autonomous memory alveolar macrophages requires T cell help and is critical to trained Immunity. Cell 175, 1634–1650 (2018).

  36. 36.

    Brown, R. L., Sequeira, R. P. & Clarke, T. B. The microbiota protects against respiratory infection via GM-CSF signaling. Nat. Commun. 8, 1512 (2017).

  37. 37.

    Siegel, S. J., Tamashiro, E. & Weiser, J. N. Clearance of pneumococcal colonization in infants is delayed through altered macrophage traance of pneumococcal colonization in infants is delayed through altered macrophage trafficking. PLoS Pathog. 11, e1005004 (2015).

  38. 38.

    Lee, W. J. & Hase, K. Gut microbiota-generated metabolites in animal health and disease. Nat. Chem. Biol. 10, 416–424 (2014).

  39. 39.

    Tzelepis, F. et al. Mitochondrial cyclophilin D regulates T cell metabolic responses and disease tolerance to tuberculosis. Sci. Immunol. 3, eaar4135 (2018).

  40. 40.

    Divangahi, M. Are tolerance and training required to end TB? Nat. Reviews Immunol. 18, 661-663 (2018).

  41. 41.

    Tzelepis, F. et al. Annexin1 regulates DC efferocytosis and cross-presentation during Mycobacterium tuberculosis infection. J. Clin. Invest. 125, 752–768 (2015).

  42. 42.

    Zhang, X., R. Goncalves, and D. M. Mosser. The isolation and characterization of murine macrophages. Curr. Protoc. Immunol. Chapter 14, Unit 14.1 (2008).

  43. 43.

    Kim, J. J. et al. Host cell autophagy activated by antibiotics is required for their effective antimycobacterial drug action. Cell Host. Microbe 11, 457–468 (2012).

  44. 44.

    Divangahi, M. et al. Mycobacterium tuberculosis evades macrophage defenses by inhibiting plasma membrane repair. Nat. Immunol. 10, 899–906 (2009).

  45. 45.

    Divangahi, M., Desjardins, D., Nunes-Alves, C., Remold, H. G. & Behar, S. M. Eicosanoid pathways regulate adaptive immunity to Mycobacterium tuberculosis. Nat. Immunol. 11, 751–758 (2010).

  46. 46.

    Lau, J. T. et al. Capturing the diversity of the human gut microbiota through culture-enriched molecular profiling. Genome Med. 8, 72 (2016).

  47. 47.

    Dhariwal, A. et al. MicrobiomeAnalyst: a web-based tool for comprehensive statistical, visual and meta-analysis of microbiome data. Nucleic Acids Res. 3, W180–W188 (2017).

Download references


We thank the Surette laboratory at McMaster University for 16S rDNA sequencing and helpful discussions related to the project. This work was supported by a CIHR operating grant (MOP-130579) to I.L.K., a CIHR Foundation Grant (FDN-143273) to M.D., the generous support of J.T. Costello Memorial Research Fund, the Richard and Edith Strauss Canada Foundation, the LIoyd Carr-Harris Foundation, and Microbiome and Disease Tolerance Centre at McGill University. N.K. is a recipient of a Fonds de recherche du Québec—Santé (FRQS) Postdoctoral Fellowship. J.X. is a Canada Research Chair in Bioinformatics and Big Data Analytics, I.L.K. is a Canada Research Chair in Barrier Immunity and M.D. holds an FRQS Award and the Strauss Chair in Respiratory Diseases.

Author information

N.K. performed experiments, analyzed data, and wrote the manuscript; L.M. and G.F. performed experiments and provided technical input; A.D. performed microbiome analyses and generated figures; J.X. provided technical input and data interpretation regarding the microbiome analyses; D.M. provided financial support and conceptual input; M.D. and I.L.K. conceived the original idea, supervised the project, and wrote the manuscript.

Competing interests:

The authors declare no conflicts of interest.

Correspondence to Maziar Divangahi or Irah L. King.

Supplementary information

  1. Supplementary FigureS1

  2. Supplementary FigureS2

  3. Supplementary FigureS3

  4. Supplementary Figure legends

Rights and permissions

To obtain permission to re-use content from this article visit RightsLink.

About this article

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6